Nyxoah SA (EBR:NYXH)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 113.52M |
| Revenue (ttm) | 10.02M |
| Net Income (ttm) | -90.09M |
| Shares Out | 43.66M |
| EPS (ttm) | -2.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,304 |
| Average Volume | 95,705 |
| Open | 2.600 |
| Previous Close | 2.600 |
| Day's Range | 2.550 - 2.600 |
| 52-Week Range | 2.350 - 8.870 |
| Beta | 0.87 |
| RSI | 42.73 |
| Earnings Date | May 12, 2026 |
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]
Financial Performance
In 2025, Nyxoah's revenue was 10.02 million, an increase of 121.63% compared to the previous year's 4.52 million. Losses were -90.09 million, 52.1% more than in 2024.
Financial StatementsNews
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or t...
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 20...
Nyxoah Earnings Call Transcript: Q4 2025
2025 saw transformative growth with FDA approval and U.S. launch, driving 122% revenue growth and strong Q4 results. U.S. net revenue is expected to grow 25% sequentially in early 2026, with expanding sales coverage and improving gross margins.
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Establishe...
Nyxoah Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Genio's differentiated bilateral neuromodulation technology for sleep apnea is gaining traction in the U.S. and internationally, with strong clinical evidence, robust reimbursement, and a focused commercialization strategy. Recent CMS updates ensure reimbursement parity, and the company targets break-even at €150 million revenue with high gross margins.
Publication relating to transparency notification
REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), March 13, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 20...
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Nyxoah to Participate in the Oppenheimer 36 th Annual Healthcare MedTech & Services Conference
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)...
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law...
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext B...
Nyxoah Transcript: 44th Annual J.P. Morgan Healthcare Conference
A differentiated neurostimulation solution for sleep apnea is rapidly gaining traction in the U.S. following FDA approval, with strong clinical evidence, high patient satisfaction, and robust reimbursement. Strategic expansion and innovation are set to drive further growth.
Publication relating to transparency notification
REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026 , 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2...
Nyxoah Announces Issuance of First Tranche of Convertible Bonds
Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “...
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals
Nyxoah Transcript: Piper Sandler 37th Annual Healthcare Conference
The session highlighted rapid U.S. launch progress, strong reimbursement and surgeon adoption, and a focused expansion strategy. Financial guidance and pipeline updates indicate confidence in long-term growth, with new clinical data and technology improvements expected to drive future margin gains.
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May ...
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nyxoah to Participate in the Piper Sandler 37 th Annual Healthcare Conference
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by s...
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the La...
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, includi...
Nyxoah Earnings Call Transcript: Q3 2025
Q3 2025 saw a 56% revenue increase to €2 million, driven by a successful U.S. Genio launch and strong physician uptake. Operating loss widened due to commercial investments, but new capital raised extends cash runway into 2027. U.S. and international growth expected to accelerate in Q4.
Nyxoah Reports Third Quarter 2025 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives...
Nyxoah Transcript: Stifel 2025 Healthcare Conference
The U.S. launch targets high-volume accounts with a focused commercial team and strong early surgeon engagement. Reimbursement approvals are consistent, and future growth will be driven by innovation, Triple C label expansion, and next-gen technology. GLP-1s are seen as a market tailwind.
Nyxoah to Participate in the Stifel 2025 Healthcare Conference
Nyxoah to Participate in the Stifel 2025 Healthcare Conference Mont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology comp...